PUBLIC COMPANY
saveMemorial Sloan Kettering Cancer Center
updated 2mo ago
community read0 votes
🐶 often sniffed alongside
top 3pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
- phase2A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
- phase2Radiation Therapy Approaches for People With Prostate Cancer
- phase2A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
- phase1A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
- phase2A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
- phase2Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
- phase2Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma
🐶 Hiring Signal
News
- Third time’s the charm for Replimune as melanoma drug earns FDA greenlightReplimune’s immunotherapy for advanced melanoma faced a perilous regulatory road with two previous rejections, but the drug—to be marketed as Tudriqev—prevailed with strong support from oncologists…biospace · 10d ago
- Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapyThe FDA’s Cellular, Tissue and Gene Therapies advisory committee voted 10 to 3 in favor of Replimune’s immunotherapy for advanced melanoma in combination with Bristol Myers Squibb’s Opdivo, but tri…biospace · 17d ago
- Dr Postow on an Ideal Post-ICI Monitoring Framework in MelanomaMichael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.onclive · 3mo ago
- Dr Postow on the Timing of Delayed or Re-Emergent irAEs in MelanomaMichael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.onclive · 3mo ago
- Dr Mauro on the Significance of Alternative TKI Formulations in CMLMichael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.onclive · 3mo ago
- Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.onclive · 3mo ago
- STAT+: In her own words: Surgeon general nominee Nicole Saphier expresses enthusiasm and caution for MAHAExamining the past statements and writings of Trump's third surgeon general nominee, Dr. Nicole Saphier, on vaccines, autism, peptides, diet and more.stat · 3mo ago
- Trump drops Casey Means as surgeon general nominee, opts for radiologist Nicole SaphierTrump slammed Sen. Bill Cassidy for blocking his surgeon general pick, as he nominated a replacement.stat · 3mo ago
- Revolution drug shows promise in early pancreatic cancerThe findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and generate billions in sales.biopharma_dive · 3mo ago
comments(0)
5-min edit window · permanent after that